Naozumi Harada
Tokyo, 1030022, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Clinical Efficacy with Evolocumab among Japanese Patients in PROFICIO: A Pooled Analysis of 1,040 Patients.
Journal: Journal of atherosclerosis and thrombosis
Published: April 16, 2026
Antitumor immune response elicited by M2 TAM-specific DDS via C-type lectin CD209b using cholesteryl pullulan nanogel as a protein drug carrier.
Journal: Biomaterials science
Published: March 17, 2025
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
Journal: International journal of cancer
Published: September 18, 2022
Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: February 23, 2022
Identification of a dominant CD8+ CTL epitope in the SARS-associated coronavirus 2 spike protein.
Journal: Vaccine
Published: July 29, 2020
MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours.
Journal: BMC cancer
Published: February 25, 2020
First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.
Journal: Cancer immunology, immunotherapy : CII
Published: March 22, 2019
NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma.
Journal: Oncotarget
Published: July 27, 2018
Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance.
Journal: The Journal of clinical investigation
Published: September 27, 2017
Last Updated: 09/26/2026